导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.00% | 1458/4773 |
| 近一周 | -2.35% | 1899/5462 |
| 近一月 | -4.80% | 2764/5421 |
| 近一季 | -8.83% | 2980/5209 |
| 近半年 | -6.32% | 3061/4920 |
| 近一年 | 7.54% | 1291/4366 |
| 近两年 | 67.19% | 1029/2954 |
| 近三年 | 33.89% | 904/2253 |
| 成立以来 | 56.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.22% 1008/4961 |
18.14% 1415/5312 |
- - |
- - |
| 2025 | 28.63% 1469/4813 |
1.88% 1527/3635 |
1.68% 2234/4076 |
23.07% 1583/4524 |
0.89% 1687/4813 |
| 2024 | 5.98% 1796/3463 |
-2.73% 1419/2808 |
-5.19% 1666/3014 |
15.11% 1811/3129 |
-0.16% 1333/3463 |
| 2023 | -6.61% 862/2656 |
6.99% 620/2280 |
-4.22% 1099/2385 |
-4.68% 1198/2515 |
-4.39% 1000/2655 |
| 2022 | -18.75% 749/2207 |
-13.41% 753/1919 |
2.49% 1294/2016 |
-10.46% 406/2113 |
2.25% 1005/2208 |
| 2021 | 13.54% 352/1822 |
-2.05% 574/1255 |
8.50% 618/1330 |
3.92% 391/1466 |
2.81% 513/1822 |
| 2020 | 21.13% 695/1250 |
-3.78% 321/1028 |
16.49% 435/1067 |
5.53% 911/1164 |
2.40% 990/1184 |
| 2019 | - - |
- - |
-7.21% 545/788 |
1.70% 368/850 |
6.19% 644/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦中证500ETF联接C VS. 长安沪深300非周期A(740101) |